(Q54250188)

26 May 2018

title

Toremifene and tamoxifen in advanced breast cancer--a double-blind cross-over trial. (English)

1 reference

26 May 2018

1 reference

L E Stenbygaard

1

1 reference

26 May 2018

J Herrstedt

2

1 reference

26 May 2018

J F Thomsen

3

1 reference

26 May 2018

K R Svendsen

4

1 reference

26 May 2018

S A Engelholm

5

1 reference

26 May 2018

P Dombernowsky

6

1 reference

26 May 2018

language of work or name

English

0 references

publication date

1 January 1993

1 reference

26 May 2018

Breast Cancer Research and Treatment

published in

1 reference

26 May 2018

volume

25

1 reference

26 May 2018

issue

1

1 reference

26 May 2018

page(s)

57-63

1 reference

26 May 2018

https://scigraph.springernature.com/pub.10.1007/bf00662401

exact match

0 references

cites work

Evaluation of tamoxifen dose in advanced breast cancer: a progress report

1 reference

12 December 2020

Alternative mechanism of action of "anti-oestrogens" in breast cancer

1 reference

12 December 2020

High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer. An ongoing phase II multicenter Finnish-Latvian cooperative study

1 reference

12 December 2020

Impact of standardization of estrogen and progesterone receptor assays of breast cancer biopsies in Denmark.

1 reference

12 December 2020

Phase I study of toremifene in patients with advanced cancer

1 reference

12 December 2020

A new triphenylethylene compound, Fc-1157a. II. Antitumor effects.

1 reference

12 December 2020

Phase II clinical study of high-dose toremifene in patients with advanced breast cancer

1 reference

12 December 2020

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

12 December 2020

Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study

1 reference

12 December 2020

Tamoxifen-induced remission in breast cancer by escalating the dose to 40 mg daily after progression on 20 mg daily: a case report and review of the literature

1 reference

12 December 2020

A new triphenylethylene compound, Fc-1157a. I. Hormonal effects

1 reference

12 December 2020

Endocrine therapy of advanced breast cancer

1 reference

12 December 2020

Phase II clinical study of toremifene in patients with metastatic breast cancer. Preliminary communication

1 reference

12 December 2020

Phase II study of high dose toremifene in advanced breast cancer progressing during tamoxifene treatment

1 reference

12 December 2020

Charts for the early stopping of pilot studies

1 reference

12 December 2020

Toremifene, a new antiestrogenic compound in the treatment of metastatic mammary cancer. A phase II study

1 reference

12 December 2020

Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association

1 reference

12 December 2020

Phase III studies of toremifene in metastatic breast cancer.

1 reference

12 December 2020

Immunohistochemical demonstration of estrogen receptors (ER) in formalin-fixed, paraffin-embedded human breast cancer tissue by use of a monoclonal antibody to ER.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00662401

1 reference

26 May 2018

1 reference

26 May 2018